دورية أكاديمية
Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth.
| العنوان: | Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth. |
|---|---|
| المؤلفون: | Rath N; Cancer Research UK Beatson Institute, Glasgow, United Kingdom., Munro J; Cancer Research UK Beatson Institute, Glasgow, United Kingdom., Cutiongco MF; Division of Biomedical Engineering, School of Engineering, University of Glasgow, Glasgow, United Kingdom., Jagiełło A; Division of Biomedical Engineering, School of Engineering, University of Glasgow, Glasgow, United Kingdom., Gadegaard N; Division of Biomedical Engineering, School of Engineering, University of Glasgow, Glasgow, United Kingdom., McGarry L; Cancer Research UK Beatson Institute, Glasgow, United Kingdom., Unbekandt M; Cancer Research UK Beatson Institute, Glasgow, United Kingdom., Michalopoulou E; Cancer Research UK Beatson Institute, Glasgow, United Kingdom., Kamphorst JJ; Cancer Research UK Beatson Institute, Glasgow, United Kingdom.; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Sumpton D; Cancer Research UK Beatson Institute, Glasgow, United Kingdom., Mackay G; Cancer Research UK Beatson Institute, Glasgow, United Kingdom., Vennin C; The Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, Australia.; St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Kensington, Australia., Pajic M; The Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, Australia.; St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Kensington, Australia., Timpson P; The Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, Australia.; St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Kensington, Australia., Olson MF; Cancer Research UK Beatson Institute, Glasgow, United Kingdom. m.olson@beatson.gla.ac.uk.; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. |
| المصدر: | Cancer research [Cancer Res] 2018 Jun 15; Vol. 78 (12), pp. 3321-3336. Date of Electronic Publication: 2018 Apr 18. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res |
| أسماء مطبوعة: | Publication: Baltimore, Md. : American Association for Cancer Research Original Publication: Chicago [etc.] |
| مواضيع طبية MeSH: | 2-Hydroxyphenethylamine/*analogs & derivatives , Antineoplastic Combined Chemotherapy Protocols/*pharmacology , Carcinoma, Pancreatic Ductal/*drug therapy , Pancreatic Neoplasms/*drug therapy , Protein Kinase Inhibitors/*pharmacology , Pyrazoles/*pharmacology , rho-Associated Kinases/*antagonists & inhibitors, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/analogs & derivatives ; 2-Hydroxyphenethylamine/pharmacology ; 2-Hydroxyphenethylamine/therapeutic use ; Amides/pharmacology ; Amides/therapeutic use ; Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Pancreatic Ductal/pathology ; Cell Line, Tumor/transplantation ; Cell Movement/drug effects ; Disease Models, Animal ; Female ; HEK293 Cells ; Humans ; Male ; Mice ; Neoplasm Invasiveness/pathology ; Neoplasm Invasiveness/prevention & control ; Pancreatic Neoplasms/pathology ; Phosphorylation/drug effects ; Protein Kinase Inhibitors/therapeutic use ; Pyrazoles/therapeutic use ; Pyridines/pharmacology ; Pyridines/therapeutic use ; Signal Transduction/drug effects ; rho-Associated Kinases/metabolism |
| مستخلص: | The high mortality of pancreatic cancer demands that new therapeutic avenues be developed. The orally available small-molecule inhibitor AT13148 potently inhibits ROCK1 and ROCK2 kinases that regulate the actomyosin cytoskeleton. We previously reported that ROCK kinase expression increases with human and mouse pancreatic cancer progression and that conditional ROCK activation accelerates mortality in a genetically modified LSL-KrasG12D; LSL-p53R172H; Pdx1-Cre ; (KPC) mouse pancreatic cancer model. In this study, we show that treatment of KPC mouse and human TKCC5 patient-derived pancreatic tumor cells with AT13148, as well as the ROCK-selective inhibitors Y27632 and H1152, act comparably in blocking ROCK substrate phosphorylation. AT13148, Y27632, and H1152 induced morphologic changes and reduced cellular contractile force generation, motility on pliable discontinuous substrates, and three-dimensional collagen matrix invasion. AT13148 treatment reduced subcutaneous tumor growth and blocked invasion of healthy pancreatic tissue by KPC tumor cells in vivo without affecting proliferation, suggesting a role for local tissue invasion as a contributor to primary tumor growth. These results suggest that AT13148 has antitumor properties that may be beneficial in combination therapies or in the adjuvant setting to reduce pancreatic cancer cell invasion and slow primary tumor growth. AT13148 might also have the additional benefit of enabling tumor resection by maintaining separation between tumor and healthy tissue boundaries. Significance: Preclinical evaluation of a small-molecule ROCK inhibitor reveals significant effects on PDAC invasion and tumor growth, further validating ROCK kinases as viable therapeutic targets in pancreatic cancer. Cancer Res; 78(12); 3321-36. ©2018 AACR . (©2018 American Association for Cancer Research.) |
| References: | J Biol Chem. 1996 Mar 1;271(9):4733-40. (PMID: 8617739) Nature. 1988 Feb 4;331(6155):450-3. (PMID: 3123999) Nat Med. 2016 May 5;22(5):462-3. (PMID: 27149218) Nat Cell Biol. 2015 Dec;17(12):1556-68. (PMID: 26595383) Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5328-33. (PMID: 22431603) Biochem Biophys Res Commun. 2016 Sep 9;478(1):330-336. (PMID: 26828267) EMBO Mol Med. 2017 Feb;9(2):198-218. (PMID: 28031255) Cancer Res. 2015 Feb 1;75(3):544-53. (PMID: 25644265) Curr Opin Cell Biol. 2008 Apr;20(2):242-8. (PMID: 18282695) Biochemistry. 1992 Aug 11;31(31):7152-4. (PMID: 1322694) J Virol. 2016 Mar 28;90(8):3860-3872. (PMID: 26819309) Nature. 2015 Sep 10;525(7568):261-4. (PMID: 26308893) J Biol Chem. 2003 Mar 21;278(12):10189-94. (PMID: 12524439) Cancer Res. 2014 Jun 1;74(11):2913-21. (PMID: 24840647) Cancer Res. 2011 Feb 1;71(3):747-57. (PMID: 21266354) Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):246-51. (PMID: 20018721) Nat Chem Biol. 2009 Jul;5(7):484-93. (PMID: 19465931) Nat Rev Dis Primers. 2016 Apr 21;2:16022. (PMID: 27158978) Nature. 2012 Nov 15;491(7424):399-405. (PMID: 23103869) EMBO Rep. 2012 Oct;13(10):900-8. (PMID: 22964758) Nat Cell Biol. 2016 Jan;18(1):33-42. (PMID: 26619148) Curr Opin Cell Biol. 2012 Apr;24(2):277-83. (PMID: 22209238) Cancer Cell. 2003 Dec;4(6):437-50. (PMID: 14706336) Nature. 1997 Oct 30;389(6654):990-4. (PMID: 9353125) J Biol Chem. 1996 Aug 23;271(34):20246-9. (PMID: 8702756) PLoS One. 2017 Aug 25;12 (8):e0183871. (PMID: 28841710) Cancer Res. 2015 Jun 1;75(11):2272-84. (PMID: 25840982) Nat Med. 2017 Feb;23 (2):235-241. (PMID: 28024083) Nat Med. 2016 May;22(5):497-505. (PMID: 27089513) Elife. 2016 Jan 14;5:e12994. (PMID: 26765561) Nature. 2015 Feb 26;518(7540):495-501. (PMID: 25719666) Nat Protoc. 2014 Jan;9(1):182-92. (PMID: 24385148) Cancer Cell. 2005 May;7(5):469-83. (PMID: 15894267) Autophagy. 2016 Jun 2;12 (6):936-48. (PMID: 27168493) CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. (PMID: 24399786) Nat Cell Biol. 2013 Jul;15(7):751-62. (PMID: 23792690) PLoS One. 2015 Jul 28;10(7):e0134306. (PMID: 26218638) Small GTPases. 2014;5:e29846. (PMID: 25010901) J Mol Med (Berl). 2007 Jun;85(6):555-68. (PMID: 17294230) Nature. 2016 Mar 3;531(7592):47-52. (PMID: 26909576) J Surg Oncol. 1986 Apr;31(4):229-34. (PMID: 3724177) J Neurochem. 2002 Apr;81(1):9-16. (PMID: 12067241) Sci Transl Med. 2017 Apr 5;9(384):. (PMID: 28381539) Oncotarget. 2017 Jan 17;8(3):4484-4500. (PMID: 27835861) Clin Cancer Res. 2012 Jul 15;18(14):3912-23. (PMID: 22781553) Small GTPases. 2017 Oct 3;:1-8. (PMID: 28972449) |
| معلومات مُعتمدة: | A17196 United Kingdom CRUK_ Cancer Research UK; A18276 United Kingdom CRUK_ Cancer Research UK; 17728 United Kingdom CRUK_ Cancer Research UK; 648892 International ERC_ European Research Council; A17728 United Kingdom CRUK_ Cancer Research UK |
| المشرفين على المادة: | 0 (2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine) 0 (AT13148) 0 (Amides) 0 (Protein Kinase Inhibitors) 0 (Pyrazoles) 0 (Pyridines) 138381-45-0 (Y 27632) 7568-93-6 (2-Hydroxyphenethylamine) 84477-87-2 (1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine) EC 2.7.11.1 (rho-Associated Kinases) |
| تواريخ الأحداث: | Date Created: 20180420 Date Completed: 20190730 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC6005347 |
| DOI: | 10.1158/0008-5472.CAN-17-1339 |
| PMID: | 29669760 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1538-7445 |
|---|---|
| DOI: | 10.1158/0008-5472.CAN-17-1339 |